Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06362044
Status:
RECRUITING
Last Update Posted:
2024-04-12
First Post:
2024-04-09
Brief Title:
A Study to Assess Frequency of Undetectable Minimal Residual Disease uMRD in Adult Participants With Chronic Lymphocytic Leukemia CLL Receiving Oral Venetoclax Tablets Intravenously IV Infused Rituximab in Routine Clinical Practice in Japan
Sponsor:
AbbVie
Organization:
AbbVie
Study Overview
Official Title:
The Frequency of uMRD in Japanese Patients With CLL After 24 Months of Treatment With VenetoclaxRituximab in the 2L in the Real-World Setting
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Most cases of Chronic lymphocytic leukemia CLL remain an incurable disease with the goal of therapy being to improve quality of life and to prolong survival This study will evaluate the participants related outcomes and experience of CLL in adult participants who are treated in the Japan
Study participants will receive oral treatments of VenetoclaxRituximab for CLL as prescribed by their study doctor in accordance with approved local label Adult participants prescribed various treatments VenetoclaxRituximab will be enrolled Around 89 participants will be enrolled in the study in sites in Japan
Participants will receive oral venetoclax tablets intravenously IV infused rituximab treatments for CLL according to the approved local label The overall study duration will be 27 months
There is expected to be no additional burden for participants in this trial All study visits will occur during routine clinical practice
Study participants will receive oral treatments of VenetoclaxRituximab for CLL as prescribed by their study doctor in accordance with approved local label Adult participants prescribed various treatments VenetoclaxRituximab will be enrolled Around 89 participants will be enrolled in the study in sites in Japan
Participants will receive oral venetoclax tablets intravenously IV infused rituximab treatments for CLL according to the approved local label The overall study duration will be 27 months
There is expected to be no additional burden for participants in this trial All study visits will occur during routine clinical practice
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None